Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eyelash Growth Drug Gets Panel Nod, Relying On Data From Use In Glaucoma

Executive Summary

Confident in the safety and efficacy data from 13 years of clinical development and post-marketing information on Allergan's glaucoma drug Lumigan, and well aware the new indication is not for medical use, the Dermatologic and Ophthalmic Drugs Advisory Committee unanimously favored approval of bimatoprost for eyelash growth stimulation Dec. 5
Advertisement

Related Content

Allergan Bats Its Eyes At Consumers With Latisse Marketing Campaign
Allergan Bats Its Eyes At Consumers With Latisse Marketing Campaign
End Of The Year Approvals And Actions, In Brief
End Of The Year Approvals And Actions, In Brief
Advertisement
UsernamePublicRestriction

Register

PS050441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel